Abstract
Background: Phospholipid transfer protein (PLTP) regulates high density lipoprotein (HDL) remodelling by transferring cholesterol and phospholipids and affecting particle size and function. Pregnancy alters lipid metabolism, but the adaptation of PLTP to pregnancy remains poorly understood. This study investigated longitudinal changes in PLTP gene expression and concentration through healthy pregnancy and pregnancy with cardiometabolic complications, as well as their associations with maternal lipid metabolism and inflammatory status.
Methods: We followed 84 healthy and 20 pregnant women who developed gestational diabetes mellitus and hypertensive disorders during pregnancy. PLTP gene expression, PLTP concentration, advanced lipid profile parameters and inflammatory status were analyzed throughout trimesters.
Results: A comparable trajectory of changes in PLTP gene expression and PLTP concentrations was observed in both groups, but PLTP gene expression in the first trimester was significantly lower in the group with complications (p < 0.05). Analysis of serum non-cholesterol sterols in HDL subfractions (NCSHDL) and plasma ceramides [ceramide C16:0 (Cer C16:0), ceramide C24:0 (Cer C24:0)], has revealed significantly lower desmosterolHDL (p < 0.05), while significantly higher C24:0 (p < 0.001) concentrations in the group with complications in the first trimester. Higher levels of resistin (p < 0.05) were found in the first trimester in the group with complications. PLTP gene expression in the first trimester was independently associated with pregnancy complications.
Conclusions: Our results showed altered PLTP gene expression, advanced lipid profile, and inflammatory status in the first trimester of pregnancy with cardiometabolic complications. Our findings emphasize the importance of a thorough investigation of lipid metabolism and inflammatory pathways in early pregnancy to improve the outcomes.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.